NeoNeuro

NeoNeuro is a private French biotech and diagnostics company focused on aptamer-based biomarker discovery and blood testing for Alzheimer's disease and related neurological disorders. The company developed the Aptamarker Platform, which uses enriched aptamer libraries, next-generation sequencing, and machine learning to identify blood-based molecular signatures associated with brain amyloid and disease progression. Its lead effort is a pre-clinical blood diagnostic test intended to detect Alzheimer's-related risk biology earlier and more cost-effectively than conventional approaches. NeoNeuro has received support from the Alzheimer's Drug Discovery Foundation and Roche-sponsored innovation programs, and has collaborated with cohorts such as AIBL and INSIGHT. The company appears to operate as the European subsidiary or predecessor brand of NeoVentures Biotechnology Europe.